Gompelman Michelle, Wouters Yannick, Kievit Wietske, Hopman Joost, Wertheim Heiman F, Bleeker-Rovers Chantal P, Wanten Geert J A
Department of Gastroenterology & Hepatology I Infectious Diseases, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands.
Trials. 2018 Jun 28;19(1):346. doi: 10.1186/s13063-018-2732-2.
Patients with long-term intestinal failure are usually treated by means of home parenteral nutrition (HPN) where they administer their nutritional formulation intravenously via a central venous access device (mostly a catheter). This implies that such patients are exposed to a lifelong risk of developing Staphylococcus aureus bacteremia (SAB). SAB poses a threat to both catheter and patient survival and may lead to frequent hospitalization and a permanent loss of vascular access. In other clinical settings, S. aureus carriage eradication has been proven effective in the prevention of S. aureus infections. Unfortunately, there is a complete lack of evidence in HPN support on the most effective and safe S. aureus decolonization strategy in S. aureus carriers. We hypothesized that long-term S. aureus decolonization in HPN patients can only be effective if it is aimed at the whole body (nasal and extra-nasal) and is given chronically or repeatedly on indication. Besides this, we believe that S. aureus carriage among caregivers, who are in close contact with the patient, are of great importance in the S. aureus transmission routes.
METHODS/DESIGN: The CARRIER trial is a randomized, open-label, multicenter clinical trial in Dutch and Danish hospitals that treat patients on HPN. A total of 138 adult HPN patients carrying S. aureus will be randomly assigned to a search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment, or a continuous suppression (CS) strategy, a repeated chronic topical antibiotic treatment. The primary outcome measure is the proportion of patients in whom S. aureus is totally eradicated during a 1-year period. Secondary outcomes are time to successful eradication, long-term antimicrobial resistance, adverse events, patient compliance, incidence of (S. aureus) infections, catheter removals, mortality rates, S. aureus transmission routes, quality of life, and health care costs.
The CARRIER trial is designed to identify the most safe and effective long-term S. aureus carriage decolonization strategy in HPN patients. This will eventually lead to a better understanding of long-term S. aureus decolonization treatments in general. The results of this study will have a great impact on our daily clinical practice, which eventually may result in less S. aureus-related infections.
ClinicalTrials.gov; NCT03173053 . Registered on 1 June 2017.
长期肠衰竭患者通常采用家庭肠外营养(HPN)治疗,即通过中心静脉通路装置(大多为导管)静脉输注营养制剂。这意味着此类患者终生面临发生金黄色葡萄球菌菌血症(SAB)的风险。SAB对导管和患者生存均构成威胁,可能导致频繁住院及永久性血管通路丧失。在其他临床环境中,已证实根除金黄色葡萄球菌携带可有效预防金黄色葡萄球菌感染。遗憾的是,在HPN支持方面,对于金黄色葡萄球菌携带者最有效、安全的金黄色葡萄球菌去定植策略完全缺乏证据。我们推测,HPN患者长期金黄色葡萄球菌去定植只有针对全身(鼻腔及鼻腔外)且根据指征长期或反复进行才会有效。除此之外,我们认为,与患者密切接触的护理人员的金黄色葡萄球菌携带情况在金黄色葡萄球菌传播途径中非常重要。
方法/设计:CARRIER试验是一项在荷兰和丹麦医院开展的随机、开放标签、多中心临床试验,这些医院为接受HPN治疗的患者提供治疗。总共138例携带金黄色葡萄球菌的成年HPN患者将被随机分配至“搜索并清除”(SD)策略组,即进行快速、短期的全身性抗生素治疗,或“持续抑制”(CS)策略组,即反复进行长期局部抗生素治疗。主要结局指标是在1年期间金黄色葡萄球菌被完全根除的患者比例。次要结局包括成功根除的时间、长期抗菌药物耐药性、不良事件、患者依从性、(金黄色葡萄球菌)感染发生率、导管拔除情况、死亡率、金黄色葡萄球菌传播途径、生活质量和医疗费用。
CARRIER试验旨在确定HPN患者最安全、有效的长期金黄色葡萄球菌携带去定植策略。这最终将有助于总体上更好地理解长期金黄色葡萄球菌去定植治疗。本研究结果将对我们的日常临床实践产生重大影响,并最终可能减少与金黄色葡萄球菌相关的感染。
ClinicalTrials.gov;NCT03173053。于2017年6月1日注册。